Here are the 10-K annual reports from Anebulo Pharmac Inc (ANEB) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow ANEB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ANEB filings page.
Anebulo Pharmaceuticals (ANEB) filed its Form 10-K reporting 41,084,731 shares outstanding and a market value of approximately $15,057,677 based on the Nasdaq close on December 31, 2024. The company recorded an accumulated deficit of $73.9 million as of June 30, 2025 and expects to continue generating operating losses. Management states cash, cash equivalents and available funding under its Loan Agreement should fund operations for at least 12 months from issuance of the financial statements. During the year the company completed a private placement of 15,151,514 shares for gross proceeds of about $15.0 million and issued warrants exercisable at $4.215 until September 28, 2027. Grant income of $0.9 million was recognized and a Loan Agreement providing up to $10 million remains available with no balance outstanding at June 30, 2025.